Streptomyces
rubellomurinus produces an antibiotic possessing Gram-negative antibacterial activity1) with the chemical structure given in Fig. 1 -A. FR-31564, a synthetic analog with the structure shown in Fig. 1 by Banyu Pharmaceutical Co., Ltd., Tokyo, Japan; piperacillin (T-1220) by Toyama Chemical Co., Ltd., Toyama, Japan; and ticarcillin (TIPC) by Beecham Laboratories, Betchworth, England.
Bacterial strains
Standard strains of pathogenic bacteria maintained in the Fujisawa Research Laboratories were used. Clinical isolates were supplied by several hospitals in Japan. 
Measurement of antibacterial activity in vitro
The antibacterial activity of the test antibiotics was determined by the agar dilution method. Unless otherwise specified, each strain was cultured in nutrient broth (Eiken, Japan) at 37°C for 20 hours. These cultures were diluted 1,000-fold and inoculated with a multiple inoculator onto nutrient agar (Difco, Detroit, U.S.A.) containing graded concentrations of the test drugs. The minimum inhibitory concentrations (MICs) were determined after incubation at 37°C for 18-20 hours. To determine the effect of blood on MICs of the test antibiotics, nutrient agar (Difco) supplemented with 10% defibrinated rabbit blood was used as the test medium. Nutrient broth (Eiken, Japan) supplemented with 10% horse serum was used for preculture of Streptococcus species. Nutrient agar (Difco) with 10% chocolatized rabbit blood was used to determine the activity of antibiotics against Streptococcus species and Neisseria gonorrhoeae.
4.
Experimental infections in mice
Male ICR-strain mice, weighing 23± 1.5 g were used in groups of 10. Each challenge organism Table 1 . Antibacterial spectra of FR-31564 and fosfomycin.
was suspended in 2.5 or 5 % gastric mucin (INC Pharmaceuticals Inc., Cleveland, U.S.A.) at conventional inoculum sizes. A 0.5-ml cell suspension of the organism was injected intraperitoneally and the test antibiotics were given subcutaneously twice at I and 3 hours after challenge. The mice were observed for 4 days and the therapeutic effect of the test drugs was expressed in terms of ED50 (mg/kg) values calculated by the Probit method3).
Results

1.
Antibacterial Spectrum.
The antibacterial spectrum of FR-31564 comparing it with that of fosfomycin is given in Table  1 . FR-31564 exerted antibacterial activity against most of the Gram-negative bacteria tested except S.
inarcescens and glucose-nonfermenting Gram-negative rods excluding P. aeruginosa and also against P. aeraginosa, Ci freandii and Etterobacter species that are relatively resistant to /-lactam antibiotics.
Unlike fosfomycin, FR-31564 was inactive against Gram-positive bacteria. The antibacterial activity of FR-31564 against several organisms including E. coli and K. pneumoniae, like that of fosfomycin, was enhanced by adding 10% rabbit blood to the test medium.
Influence of Various Culture Conditions on Antibacterial
Activity ( inconstans B were 125 and 10.4 /cg/ml respectively. The antibacterial activity of FR-31564 was less than that of fosfomycin against P. morganii and almost the same as that of fosfomycin against P. inconstans B. The mean MICs of FR-31564 for 50 strains of Enterobacter aerogenes and 100 strains each of Enterobacter cloacae and Ci freundii were 6.70, 1.80 and 2.72 /ig/ml respectively. The MICs of FR-31564 against Enterobacter species were lower than those of fosfomycin but were almost the same against Citrobacter. For 50 strains each of P. aeruginosa and S. marcescens, the mean MICs of FR-31564 were 9.74 and 33.9 /cg/ml respectively. FR-31564 was more active than fosfomycin against P. aeruginosa, but was less active than fosfomycin against S. marcescens. For 50 strains each of Salmonella species and Shige/la species, the respective mean MICs of FR-31564 were 4.01 and 3.79 /eg/ml, and were almost the same as those of fosfomycin.
Influence of Blood on Antibacterial Activity of FR-31564
Since the antibacterial activity of FR-31564 against E. coli NIHJ JC-2 (Table 2) is enhanced in the presence of blood, we studied the effect of blood on the antibacterial activity of FR-31564 against various clinical isolates (Table 4 ). The mean MICs of FR-31564 for 50 strains each of E. coli and K.
pneumoniae in the absence of blood were 5.37 and 6.34 /cg/ml respectively. However, the antibacterial activity of FR-31564 was enhanced in the presence of blood, and the MICs were 0.85 and 2.18 /ag/ml respectively. Likewise, the antibacterial activity of FR-31564 against P. rettgcri, P. morganii, P. inconstans B, E. aerogenes, E. cloacae, C. freu,,dii and Shigella sonnei II was enhanced in the presence of blood. A similar effect of blood with FR-31564 was also obtained with fosfomycin for most of the organisms tested. The results of the antibacterial activity of FR-31564 in the presence or absence of blood showed that FR-31564 was active against E. coli, K. pneumoniae, P. mirabilis, the indole-positive Proteus group, Enterobacter species, C. freundii, P. aeruginosa, Salmonella species and Shigella species but was inactive against pathogenic Gram-positive bacteria including S. aureus as well as S. marcescens and glucose-nonfermenting Gram-negative rods excepting P. aeruginosa. Nutrient agar (Difco), 37°C, 20 hours, stamp method. Inoculum size: 1,000-fold dilution to other drugs. FR-31564 was active against 17 strains of E. coli highly resistant to ampicillin (mean MIC: > 400 pg/ml), the MIC being 4.8 ,ug/ml. Four strains of cefazolin-resistant K. pneumoniae (mean MIC: 82 /tg/ml) were susceptible to FR-31564, the mean MICs of FR-31564 and fosfomycin being 2.20 and 12.5 lcg/m] respectively. FR-31564 was active against 4 strains of ampicillin-resistant P. mirabilis (mean MIC: 160 /.cg/ml), 13 strains of piperacillin-resistant E. aerogenes (mean MIC: 100pg/ml) and 15 strains of piperacillin-resistant C. freundii (mean MIC: 160,ug/ml) with MICs of 2.60, 4.50 and 2.40pg/ml respectively. FR-31564 was active against all 7 strains each of ticarcillin-and gentamicinresistant P. aeruginosa (mean MIC: 210 and 100 ,ug/ml respectively), the mean MICs of FR-31564 The therapeutic effect of FR-31564 after subcutaneous dosing was studied in experimental infections in mice (Table 6 ). The therapeutic effect of FR-31564 was superior to that of fosfomycin against infections due to 8 of the 11 species of bacteria tested except P. mirabilis, P. morganii and E. aerogenes.
Antibacterial Activity of FR-31564 against Gram-negative Bacteria Resistant to Other Antibiotics
Namely, the protective effect of FR-31564 against infections due to E. coli strain 23 and K. pneumoniae strain 13 was similar to that of gentamicin and was more potent than that of fosfomycin and piperacillin. Antibiotic FR-31564 was effective against infection due to E. cloacae strain 63, whereas fosfomycin was not effective against infection due to the same bacteria. The activity of FR-31564 was similar to fosfomycin activity against infection due to P. mirabilis strain 60, but was less effective than fosfomycin against infection due to P. morganii strain 64.
However, the protective effect of FR-31564 was superior to that of fosfomycin against all infections due to P. vulgaris strain 8, P. rettgeri strain 34, P. inconstans B strain 21 and was similar to that of gentamicin against infections due to the latter 2 pathogens. The protective effect of FR-31564 against P. aeruginosa strain 26 was the most potent of the 5 drugs including gentamicin. 
